Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Lovage (Levisticum officinale) demonstrates anti-inflammatory activity through its primary bioactive compound ligustilide, which inhibits lipoxygenase (LOX) and cyclooxygenase-2 (COX-2) enzymes. The herb's alkyl-phthalide compounds, particularly Z-ligustilide and butylidene-phthalide, contribute to its diuretic and antioxidant properties.
Reported Benefits (Provisional)
Origin & History
Levisticum officinale, commonly known as Lovage, is a perennial herb native to the Mediterranean region, now widely cultivated across Europe, North America, and Asia. Prized for its strong celery-like flavor and aromatic qualities, its leaves, stems, seeds, and roots are valued in functional nutrition for their digestive, antioxidant, and anti-inflammatory properties.
Research Narrative (Provisional)
Scientific studies support Lovage's traditional uses, validating its diuretic, antioxidant, and anti-inflammatory properties. Research highlights its potential in supporting digestive, respiratory, and cardiovascular health, with ongoing investigations into its bioactive compounds.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Dietary Fiber - Vitamins: Vitamin C, B vitamins - Minerals: Potassium, Magnesium, Calcium, Iron - Phytochemicals: Essential oils (eugenol, limonene, thymol, ligustilide), Quercetin, Rutin, Coumarins, Furanocoumarins, Flavonoids, Polyphenols
Reported Mechanism (Provisional)
Lovage exerts its therapeutic effects through ligustilide and other alkyl-phthalide compounds that inhibit key inflammatory enzymes lipoxygenase (LOX) and cyclooxygenase-2 (COX-2), reducing prostaglandin E2 and leukotriene B4 biosynthesis. The herb also inhibits angiotensin-converting enzyme (ACE) with an EC₅₀ of 97.68 ± 8.83 mg FW/mL, contributing to its cardiovascular benefits. In cancer cells, hydroalcoholic lovage extract increases intracellular cGMP levels by inhibiting phosphodiesterase 5 (PDE5), inducing apoptosis particularly in triple-negative breast cancer cells.
Clinical Narrative (Provisional)
Current evidence for lovage is primarily based on in vitro studies and animal models rather than human clinical trials. Animal studies using cyclophosphamide-induced cystitis in rats, carrageenan-induced prostatitis in rats, and zymosan-induced peritonitis in mice demonstrated significant anti-inflammatory and analgesic effects when lovage formulations were administered orally. Laboratory studies show jasmonic acid-elicited lovage achieved lipase inhibitory activity with an EC₅₀ of 1.15 ± 0.05 mg FW/mL, while yeast extract-elicited preparations enhanced antioxidant capacity following simulated digestion. Human clinical trial data is currently lacking, limiting the strength of evidence for therapeutic applications.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.